

---

**PSILOTHERA, INC.**

**FINANCIAL STATEMENTS**  
**YEAR ENDED DECEMBER 31, 2021 AND 2020**  
***(AUDITED)***

*(Expressed in United States Dollars)*

---

## INDEX TO FINANCIAL STATEMENTS

---

|  | Page |
|--|------|
| INDEPENDENT AUDITOR'S REPORT .....                 | 1    |
| FINANCIAL STATEMENTS:                              |      |
| Balance Sheet .....                                | 2    |
| Statement of Operations .....                      | 3    |
| Statement of Changes in Stockholders' Equity ..... | 4    |
| Statement of Cash Flows .....                      | 5    |
| Notes to Financial Statements .....                | 6    |

---

## INDEPENDENT AUDITOR'S REPORT

To the Board of Directors  
Psilothera, Inc.  
Henderson, NV US

### Opinion

We have audited the financial statements of Psilothera Inc., which comprise the balance sheet as of December 31, 2021, and the related statement of income, changes in stockholders' equity, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of Psilothera Inc. as of December 31, 2021, and the result of its operations and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

### Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Psilothera Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

### Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Psilothera Inc.'s ability to continue as a going concern for a reasonable period of time, not to exceed one year beyond the date of the financial statements being audited.

### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users made on the basis of these financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Psilothera Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Psilothera Inc.'s ability to continue as a going concern for a reasonable period of time

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

### **Going Concern**

As discussed in Note 8, certain conditions indicate that the Company may be unable to continue as a going concern. The accompanying financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SetApart FS

April 15, 2022  
Los Angeles, California

**PSILOTHERA INC.**  
**BALANCE SHEET**

| <b>As of December 31,</b>                         | <b>2021</b>     | <b>2020</b> |
|---|-----------------|-------------|
| (USD \$ in Dollars)                               |                 |             |
| <b>ASSETS</b>                                     |                 |             |
| Current Assets:                                   |                 |             |
| Cash, cash equivalents & restricted cash          | \$ 2,293        | \$ -        |
| <b>Total current assets</b>                       | <b>2,293</b>    | <b>-</b>    |
| <b>Total assets</b>                               | <b>\$ 2,293</b> | <b>\$ -</b> |
| <b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>       |                 |             |
| Current Liabilities:                              |                 |             |
| Shareholders loan                                 | 40,000          | -           |
| Other current liabilities                         | 8,100           | -           |
| <b>Total current liabilities</b>                  | <b>48,100</b>   | <b>-</b>    |
| <b>Total liabilities</b>                          | <b>48,100</b>   | <b>-</b>    |
| <b>STOCKHOLDERS' EQUITY</b>                       |                 |             |
| Common Stock                                      | 1,000           | 930         |
| Additional Paid in Capital                        | 105,443         | (930)       |
| Retained earnings/(Accumulated Deficit)           | (152,250)       | -           |
| <b>Total stockholders' equity</b>                 | <b>(45,807)</b> | <b>-</b>    |
| <b>Total liabilities and stockholders' equity</b> | <b>\$ 2,293</b> | <b>\$ -</b> |

*See accompanying notes to financial statements.*

**PSILOTHERA INC.**  
**STATEMENTS OF OPERATIONS**

---

| For Fiscal Year Ended December 31,              | 2021                | 2020        |
|---|---------------------|-------------|
| (USD \$ in Dollars)                             |                     |             |
| Net revenue                                     | \$ -                | \$ -        |
| Cost of goods sold                              | -                   | -           |
| Gross profit                                    | -                   | -           |
| Operating expenses                              |                     |             |
| General and administrative                      | 117,805             | -           |
| Sales and marketing                             | 32,445              | -           |
| Total operating expenses                        | 150,250             | -           |
| Operating income/(loss)                         | (150,250)           | -           |
| Interest expense                                | 2,000               | -           |
| Income/(Loss) before provision for income taxes | (152,250)           | -           |
| Provision/(Benefit) for income taxes            | -                   | -           |
| <b>Net income/(Net Loss)</b>                    | <b>\$ (152,250)</b> | <b>\$ -</b> |

*See accompanying notes to financial statements.*

**PSILOThERA INC.**  
**STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**

For Fiscal Year Ended December 31, 2021 and 2020

| (in thousands, \$US)                | Common Stock      |                 | Additional Paid<br>in Capital | Accumulated<br>Deficit | Total<br>Stockholders'<br>Equity |
|-------------------------------------|-------------------|-----------------|-------------------------------|------------------------|----------------------------------|
|                                     | Shares            | Amount          |                               |                        |                                  |
| Inception date (September 18, 2020) | 9,300,000         | \$ 930          | \$ (930)                      | \$ -                   | \$ -                             |
| Net income/(loss)                   | -                 | -               | -                             | -                      | -                                |
| <b>Balance—December 31, 2020</b>    | <b>9,300,000</b>  | <b>\$ 930</b>   | <b>\$ (930)</b>               | <b>\$ -</b>            | <b>\$ -</b>                      |
| Issuance of common stock            | 700,000           | 70              | 106,373                       | -                      | 106,443                          |
| Net income/(loss)                   | -                 | -               | -                             | (152,250)              | (152,250)                        |
| <b>Balance—December 31, 2021</b>    | <b>10,000,000</b> | <b>\$ 1,000</b> | <b>\$ 105,443</b>             | <b>\$ (152,250)</b>    | <b>\$ (45,807)</b>               |

See accompanying notes to financial statements.

**PSILOTHERA INC.**  
**STATEMENTS OF CASH FLOWS**

| <b>For Fiscal Year Ended December 31,</b>   | <b>2021</b>      | <b>2020</b> |
|---|------------------|-------------|
| (USD \$ in Dollars)   |                  |             |
| <b>CASH FLOW FROM OPERATING ACTIVITIES</b>  |                  |             |
| Net income/(loss)   | \$ (152,250)     | \$ -        |
| <i>Adjustments to reconcile net income to net cash provided/(used) by operating activities:</i> |                  |             |
| Changes in operating assets and liabilities:  |                  |             |
| Other current liabilities   | 8,100            | -           |
| <b>Net cash provided/(used) by operating activities</b>   | <b>(144,150)</b> | <b>-</b>    |
| <b>CASH FLOW FROM INVESTING ACTIVITIES</b>  |                  |             |
| Fixed asset purchase  | -                | -           |
| <b>Net cash provided/(used) by investing activities</b>   | <b>-</b>         | <b>-</b>    |
| <b>CASH FLOW FROM FINANCING ACTIVITIES</b>  |                  |             |
| Loans received  | 40,000           |             |
| Proceeds from Capital raised on Crowdfunding  | 106,443          | -           |
| <b>Net cash provided/(used) by financing activities</b>   | <b>146,443</b>   | <b>-</b>    |
| Change in cash  | 2,293            | -           |
| Cash, cash equivalents, and restricted cash—beginning of year                                   | -                | -           |
| <b>Cash, cash equivalents, and restricted cash—end of year</b>                                  | <b>\$ 2,293</b>  | <b>\$ -</b> |
| <b>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</b>   |                  |             |
| Cash paid during the year for interest  | \$ -             | \$ -        |
| Cash paid during the year for income taxes  | \$ -             | \$ -        |
| <b>OTHER NONCASH INVESTING AND FINANCING ACTIVITIES AND SUPPLEMENTAL DISCLOSURES</b>            |                  |             |
| Purchase of property and equipment not yet paid for   | \$ -             | \$ -        |
| Conversion of debt into equity  | \$ -             | \$ -        |

*See accompanying notes to financial statements.*



**PSILOTHERA INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR YEAR ENDED TO DECEMBER 31, 2021**

---

---

**1. NATURE OF OPERATIONS**

Psilothera Inc., was formed on September 18, 2020, in the state of Wyoming. The financial statements of Psilothera Inc. (which may be referred to as the “Company”, “we,” “us,” or “our”) are prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The Company’s headquarter is located in Henderson, NV.

Psilothera is a pioneering life sciences company, deploying technology and artificial intelligence in drug development of proprietary psilocybin (“magic mushroom”) based therapeutics.

**2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Use of Estimates**

The preparation of financial statements in conformity with United States GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

Cash and cash equivalents include all cash in banks. The Company’s cash is deposited in demand accounts at financial institutions that management believes are creditworthy. The Company’s cash and cash equivalents in bank deposit accounts, at times, may exceed federally insured limits. As of December 31, 2021, and December 31, 2020, the Company’s cash and cash equivalents did not exceed FDIC insured limits.

**Income Taxes**

Psilothera Inc. is a C corporation for income tax purposes. The Company accounts for income taxes under the liability method, and deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying values of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided on deferred tax assets if it is determined that it is more likely than not that the deferred tax asset will not be realized. The Company records interest, net of any applicable related income tax benefit, on potential income tax contingencies as a component of income tax expense. The Company records tax positions taken or expected to be taken in a tax return based upon the amount that is more likely than not to be realized or paid, including in connection with the resolution of any related appeals or other legal processes. Accordingly, the Company recognizes liabilities for certain unrecognized tax benefits based on the amounts that are more likely than not to be settled with the relevant taxing authority. The Company recognizes interest and/or penalties related to unrecognized tax benefits as a component of income tax expense. The Company has filed its corporate income tax return for the period ended December 31, 2020. The income tax returns will remain subject to examination by the Internal Revenue Service under the statute of limitations for a period of three years from the date it is filed. The Company incurred a loss during the period from inception through December 31, 2020 and carries a federal net operating loss that can be used to offset future corporate taxable income (to extent allowed by law).

**PSILOTHERA INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR YEAR ENDED TO DECEMBER 31, 2021**

---

---

**Revenue Recognition**

The Company adopted ASU 2014-09, *Revenue from Contracts with Customers*, and its related amendments (collectively known as “ASC 606”), effective May 24, 2019. The Company determines revenue recognition through the following steps:

- Identification of a contract with a customer;
- Identification of the performance obligations in the contract;
- Determination of the transaction price;
- Allocation of the transaction price to the performance obligations in the contract; and
- Recognition of revenue when or as the performance obligations are satisfied.

Revenue is recognized when performance obligations are satisfied through the transfer of control of promised goods to the Company's customers in an amount that reflects the consideration expected to be received in exchange for transferring goods or services to customers. Control transfers once a customer has the ability to direct the use of, and obtain substantially all of the benefits from, the product. This includes the transfer of legal title, physical possession, the risks and rewards of ownership, and customer acceptance.

The Company has not yet earned revenue, as it continues to be an early-stage research and development company.

**Fair Value of Financial Instruments**

The carrying value of the Company's financial instruments included in current assets and current liabilities (such as cash and cash equivalents, restricted cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term nature of such instruments.

The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:

**Level 1**—Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.

**Level 2**—Observable prices that are based on inputs not quoted on active markets but corroborated by market data.

**Level 3**—Unobservable inputs reflecting the Company's assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

**Subsequent Events**

The Company considers events or transactions that occur after the balance sheets date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through April 23, 2021, which is the date the financial statements were issued.

**PSILOTHERA INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR YEAR ENDED TO DECEMBER 31, 2021**

---

---

**Recently Issued and Adopted Accounting Pronouncements**

In February 2019, FASB issued ASU No. 2019-02, leases, that requires organizations that lease assets, referred to as "lessees", to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases with lease terms of more than 12 months. ASU 2019-02 will also require disclosures to help investors and other financial statement users better understand the amount, timing, and uncertainty of cash flows arising from leases and will include qualitative and quantitative requirements. The new standard for nonpublic entities will be effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021, and early application is permitted. We are currently evaluating the effect that the updated standard will have on the financial statements and related disclosures.

In June 2019, FASB amended ASU No. 2019-07, Compensation – Stock Compensation, to expand the scope of Topic 718, Compensation – Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. The new standard for nonpublic entities will be effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020, and early application is permitted. We are currently evaluating the effect that the updated standard will have on the financial statements and related disclosures.

In August 2019, amendments to existing accounting guidance were issued through Accounting Standards Update 2019-15 to clarify the accounting for implementation costs for cloud computing arrangements. The amendments specify that existing guidance for capitalizing implementation costs incurred to develop or obtain internal-use software also applies to implementation costs incurred in a hosting arrangement that is a service contract. The guidance is effective for fiscal years beginning after December 15, 2020, and interim periods within fiscal years beginning after December 15, 2021, and early application is permitted. We are currently evaluating the effect that the updated standard will have on the financial statements and related disclosures.

In August 2020, FASB issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity; Own Equity ("ASU 2020-06"), as part of its overall simplification initiative to reduce costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. Among other changes, the new guidance removes from GAAP separation models for convertible debt that require the convertible debt to be separated into a debt and equity component, unless the conversion feature is required to be bifurcated and accounted for as a derivative or the debt is issued at a substantial premium. As a result, after adopting the guidance, entities will no longer separately present such embedded conversion features in equity, and will instead account for the convertible debt wholly as debt. The new guidance also requires use of the "if-converted" method when calculating the dilutive impact of convertible debt on earnings per share, which is consistent with the Company's current accounting treatment under the current guidance. The guidance is effective for financial statements issued for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, but only at the beginning of the fiscal year. The Company is currently evaluating the impact the adoption of ASU 2020-06 will have on the Company's financial statements.

The FASB issues ASUs to amend the authoritative literature in ASC. There have been a number of ASUs to date, including those above, that amend the original text of ASC. Management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, (iii) are not applicable to us or (iv) are not expected to have a significant impact our financial statements.

**PSILOTHERA INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR YEAR ENDED TO DECEMBER 31, 2021**

---

### 3. CAPITALIZATION AND EQUITY TRANSACTIONS

The Company is authorized to issue 20,000,000 of Common Shares at a \$0.0001 par value. The Company does not have any other authorized classes of shares. As of December 31, 2021, and December 31, 2020, 10,000,000 shares and 9,300,000 shares have been issued and are outstanding.

### 4. DEBT

#### Shareholder Loan

During 2021 the Company's shareholders granted loans to the Company in the total amount of \$40,000 with 10% interest per annum. No agreement was put in place for the loans and no maturity dates were set. The entire debt has been classified as current as it can be called back at any time.

### 5. INCOME TAXES

The provision for income taxes for the year ended December 31, 2021, and December 31, 2020, consists of the following:

| <b>As of Year Ended December 31,</b> | <b>2021</b> | <b>2020</b> |
|--------------------------------------|-------------|-------------|
| Net Operating Loss                   | \$ (31,552) | \$ -        |
| Valuation Allowance                  | 31,552      | -           |
| <b>Net Provision for income tax</b>  | <b>\$ -</b> | <b>\$ -</b> |

Significant components of the Company's deferred tax assets and liabilities on December 31, 2021, and December 31, 2020 are as follows:

| <b>As of Year Ended December 31,</b> | <b>2021</b> | <b>2020</b> |
|--------------------------------------|-------------|-------------|
| Net Operating Loss                   | \$ (31,552) | \$ -        |
| Valuation Allowance                  | 31,552      | -           |
| <b>Net Provision for income tax</b>  | <b>\$ -</b> | <b>\$ -</b> |

Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. On the basis of this evaluation, the Company has determined that it is more likely than not that the Company will not recognize the benefits of the federal and state net deferred tax assets, and, as a result, full valuation allowance has been set against its net deferred tax assets as of December 31, 2021, and December 31, 2020. The amount of the deferred tax asset to be realized could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased.

For the fiscal year ending December 31, 2021, the Company had federal cumulative net operating loss ("NOL") carryforwards of \$150,250, and the Company had no state net operating loss ("NOL") carryforwards. Utilization of some of the federal and state NOL carryforwards to reduce future income taxes will depend on the Company's ability to generate sufficient taxable income prior to the expiration of the carryforwards. The federal net operating loss carryforward is subject to an 80% limitation on taxable income, does not expire, and will carry on indefinitely.

**PSILOTHERA INC.**  
**NOTES TO FINANCIAL STATEMENTS**  
**FOR YEAR ENDED TO DECEMBER 31, 2021**

---

---

The Company recognizes the impact of a tax position in the financial statements if that position is more likely than not to be sustained on a tax return upon examination by the relevant taxing authority, based on the technical merits of the position. As of December 31, 2021, and December 31, 2020, the Company had no unrecognized tax benefits.

The Company recognizes interest and penalties related to income tax matters in income tax expense. As of December 31, 2021, and December 31, 2020, the Company had no accrued interest and penalties related to uncertain tax positions.

## **6. RELATED PARTY**

During 2021 the Company's shareholders granted loans to the Company in the total amount of \$40,000 with 10% interest per annum. No agreement was put in place for the loans and no maturity dates were set. The entire debt has been classified as current as it can be called back at any time.

There were no other related party transactions.

## **7. COMMITMENTS AND CONTINGENCIES**

### **Contingencies**

The Company's operations are subject to a variety of local and state regulation. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.

### **Litigation and Claims**

From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2021, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company's operations.

## **8. GOING CONCERN**

These financial statements are prepared on a going concern basis. The Company began operation in 2020 and has had little activity since inception through December 31, 2020. The Company's ability to continue is dependent upon management's plan to raise additional funds and achieve profitable operations. The financial statements do not include any adjustments that might be necessary if the Company is not able to continue as a going concern.

## **9. SUBSEQUENT EVENTS**

The Company has evaluated subsequent events from December 31, 2021, through April 15, 2022, which is the date the financial statements were available to be issued.

There have been no events or transactions during this time which would have a material effect on these financial statements.